# A Study Evaluating Topical Recombinant Human Vascular Endothelial Growth Factor (Telbermin) for Induction of Healing of Chronic, Diabetic Foot Ulcers

> **NCT00069446** · PHASE1 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 50 (—)

## Conditions studied

- Foot Ulcer

## Interventions

- **DRUG:** rhuMAb VEGF (telbermin)

## Key facts

- **NCT ID:** NCT00069446
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-08
- **Primary completion:** 2004-10
- **Final completion:** 2004-10
- **Target enrollment:** 50 (—)
- **Last updated:** 2017-05-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00069446

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00069446, "A Study Evaluating Topical Recombinant Human Vascular Endothelial Growth Factor (Telbermin) for Induction of Healing of Chronic, Diabetic Foot Ulcers". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00069446. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*